FDA.reportPublic FDA data

tofacitinib 22 MG 24HR Extended Release Oral Tablet

RxCUI
2273113
RxNorm name
tofacitinib 22 MG 24HR Extended Release Oral Tablet
Display name
tofacitinib 22 MG 24HR Extended Release Oral Tablet
Full name
tofacitinib 22 MG 24HR Extended Release Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:22

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 4 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
tofacitinibTOFACITINIBZydus Pharmaceuticals USA Inc.179ffbb2-bedc-40e6-b77b-33d4f78321722026-08-07Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2273113
XELJANZTOFACITINIBU.S. Pharmaceuticals68e3d6b2-7838-4d2d-a417-09d919b43e132026-07-13Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2273113
XELJANZ XRTOFACITINIBPfizer Laboratories Div Pfizer Inccf74ba2f-afc5-4baa-8594-979c889a58312026-07-12Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2273113
tofacitinibTOFACITINIBZydus Lifesciences Limitedac0b26d5-1352-42ff-b5ea-3eb02d8508a42026-05-12Exact identifier
rxcui: 2273113

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 4 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
cf74ba2f-afc5-4baa-8594-979c889a5831tofacitinib 22 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR tofacitinib 22 MG Extended Release Oral Tablet [SCD]253These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 201220260312
68e3d6b2-7838-4d2d-a417-09d919b43e13tofacitinib 22 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR tofacitinib 22 MG Extended Release Oral Tablet [SCD]217These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 201220260327
179ffbb2-bedc-40e6-b77b-33d4f7832172tofacitinib 22 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR tofacitinib 22 MG Extended Release Oral Tablet [SCD]26These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 201220260512
ac0b26d5-1352-42ff-b5ea-3eb02d8508a4tofacitinib 22 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR tofacitinib 22 MG Extended Release Oral Tablet [SCD]25TOFACITINIB Extended-Release Tablets20260512